

# March 2026 Tender notification

30 March 2026

## What we're doing

Pharmac is announcing recent decisions from its Annual Invitation to Tender (ITT) process. This notification includes:

- details about decisions on medicines included in the 2024/25 ITT and in the 2025/26 ITT

You can see the full technical details of the tender decisions in the Tender Results section [\[link\]](#).

The table below provides a summary of the outcomes for the remaining unresolved medicines included in the May 2025 and July 2025 additional brand change consultations.

Medicine	What medicine is used for	Outcome
Calcitriol cap 0.25 mcg	A form of vitamin D, used for people with severe kidney disease to lower their parathyroid hormone (PTH) levels.	Still under consideration.
Calcitriol cap 0.5 mcg		Still under consideration.
Calcium gluconate Inj 10%	Used to treat acute hypocalcaemia; hypocalcaemic tetany; hyperkalaemia with secondary cardiac toxicity; and hypermagnesaemia.	Still under consideration.
Carmustine inj 100 mg vial	Used to treat multiple myeloma, non-Hodgkin's lymphomas, and brain tumours	<b>No brand change.</b>
Iron (as Ferric Carboxymaltose) inj 50 mg per ml, 10 ml vial	An iron infusion used to treat iron-deficiency or anemia.	Still under consideration.
Ivermectin tab 3 mg	Used to treat certain types of parasite infections, and for scabies when other treatments have not worked well.	Still under consideration.
Methenamine (hexamine) Hippurate tab 1 g	Used to prevent urinary tract infections (UTIs).	Still under consideration.
Nilotinib cap 150 mg	Used to treat newly diagnosed chronic phase Philadelphia chromosome-positive chronic myeloid leukaemia, chronic or accelerated phase Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to previous therapy.	Still under consideration.
Nilotinib cap 200 mg		Still under consideration.
Raltegravir potassium tab 600 mg	Used for the treatment of HIV-1 infection in combination with other antiretroviral drugs.	Still under consideration.

Sunscreens, propriety SPF 50+ or greater	Used to help protect your skin from the sun's damaging ultraviolet (UV) light when outdoors.	Still under consideration.
Teriparatide inj 250 mcg per ml	Used to treat osteoporosis (bone loss).	<b>Declined.</b>
Water for injection purified for inj, 500 ml bag	Used to dissolve or dilute medicines which may then be injected. It can also be used for washing and cleaning purposes during minor surgical procedures, and to clean wounds.	Still under consideration.
Xylometazoline nasal spray 0.1%	Used to help nasal congestion.	Still under consideration.

## Why we're doing this

Pharmac's annual tender process allows suppliers to bid to be the main supplier of off-patent medicines. This year's tender is expected to free up between \$30 million and \$50 million, which will be reinvested into funding new treatments.

Following feedback from previous brand changes, Pharmac introduced a new consultation step to better engage with stakeholders. In response, we received feedback on the items included in the 2024/25 ITT, which helped shape our decisions.

## How your feedback helped

The feedback received was considered as part of the decision-making process and has helped shape our implementation activities to support people through this brand change. We want to thank everyone who took the time to share their feedback. We heard from a range of people including healthcare professionals, advocacy groups and users of medicines. You provided feedback about:


- packaging and labelling considerations
- the resources and communications needed to support a brand change
- the people who may need additional support when undergoing a brand change

## Who may be most interested

- People who use funded medicines
- Healthcare professionals

- Advocacy groups
- Suppliers

If you have any questions about the decisions in this notification, you can email us at [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz); or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 660 050.



30 March 2026

## Tender results – Invitation to Tender 2024/24 & 2025/26

Pharmac has resolved to award or not award tenders for Principal Supply Status for some products included in the 2024/25 Invitation to Tender dated 31 October 2024 and in the 2025/26 Invitation to Tender dated 3 November 2025.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

### Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12<sup>th</sup> of April 2026 or the 5<sup>th</sup> of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12<sup>th</sup> of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<https://www.pgnz.org.nz/our-trading-arm-ps/>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5<sup>th</sup> of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.

**2024/25 Tender – Principal Supply Status applies until 30 June 2028**

**Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.**

The decisions were as follows:

- Tenders awarded to currently listed pharmaceuticals where no other brand is listed (no brand change)*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Carmustine <sup>1</sup>	Inj 100 mg vial; 1 vial	\$710.00	\$710.00	BiCNU (Arrotex)	1 July 2026	1 December 2026
<sup>1</sup> The price and subsidy of carmustine (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be maintained at the above price.						

**2025/26 Tender – Principal Supply Status applies until 30 June 2029**

**Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule**

The decisions were as follows:

- Tenders awarded to currently listed pharmaceuticals where no other brand is listed (no brand change)*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Paracetamol	Tab 500 mg; 1000 tab blister pack	\$19.75	\$12.06	Pacimol (Miro)	1 July 2026	1 December 2026

**Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.**

2. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed (no brand change)*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date
Paracetamol	Tab 500 mg; 1000 tab blister pack	\$19.75	\$12.06	Pacimol (Miro)	5%	1 July 2026	1 December 2026

**Tender declines – Products where no tender is to be awarded for Principal Supply Status**

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2024/25 Invitation to Tender, dated 31 October 2024.

Chemical Name	Line Item
Teriparatide (current access)	Inj 250 mcg per ml
Teriparatide (widened access)	Inj 250 mcg per ml

Pharmac has resolved not to award tenders for Principal Supply Status for the following products listed in the 2025/26 Invitation to Tender, dated 3 November 2025.

Chemical Name	Line Item
Fludarabine phosphate	Tab 10 mg
Glibenclamide	Tab 5 mg
Hyoscine (Scopolamine)	Patch 1 mg per 72 hours
Ivabradine	Tab 5 mg

Propylthiouracil	Tab 50 mg
Sodium phosphate with phosphoric acid	Enema 10% with phosphoric acid 6.58%
Telmisartan with amlodipine	Tab 40 mg with amlodipine 10 mg
Telmisartan with amlodipine	Tab 40 mg with amlodipine 5 mg
Telmisartan with amlodipine	Tab 80 mg with amlodipine 10 mg
Telmisartan with amlodipine	Tab 80 mg with amlodipine 5 mg
Triamcinolone acetonide	Crm 0.02%
Triamcinolone acetonide	Oint 0.02%

## What you told us

Please refer to [the July 2025 Tender Notification II](#) which outlines the themes identified in the consultation feedback received for medicines included in the 2024/25 ITT.